Loading...
Brentuximab Vedotin in CD30+ Lymphomas
Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin’s lymphoma (cHL) and anaplastic la...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer Healthcare
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3873074/ https://ncbi.nlm.nih.gov/pubmed/24392301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13554-013-0008-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|